Last edition
News about "CNS therapeutics "
Suven Life Sciences Reports Positive Phase 1 Results for SUVN-I6107
Suven Life Sciences has reported positive topline results from the First-in-Human phase 1 study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM). The successful trial supports the advancement of SUVN-I6107 into phase 2 clinical development.
CNS Therapeutics | 16/06/2026 | By News Bureau | 126
Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration
The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.
CNS Therapeutics | 08/04/2026 | By News Bureau | 119
CBC Group Acquires UCB's Mature Product Portfolio in China
The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market.
CNS Therapeutics | 03/12/2024 | By Aishwarya | 688
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy